



Janus Ong, M.D., M.P.H.

Advocacy Committee Head, 2012-2017; Hepatology Society of the Philippines

Find out more at: www.gilead.com/yir2017

COMMUNITY IMPACT

GILEAD MAKING A DIFFERENCE

Gilead recognizes that the development of world-class medicines for life-threatening diseases is only one aspect of improving public health. We invest significant internal resources in the management of programs that provide education, prevention, care and social and financial support for the most vulnerable communities.



*Tori Cooper, Prevention Specialist,
Positive Impact Centers, Atlanta, Georgia*

COMPASS – Southern HIV Initiative

According to the United States Centers for Disease Control and Prevention (CDC), eight of the 10 states with the highest rates of new HIV diagnoses are in the South. Southern states today account for an estimated 44 percent of all people living with HIV in the United States.

To help address this epidemic, the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative™ was launched in 2017 with a groundbreaking \$100 million commitment over 10 years. Gilead partnered with three lead coordinating centers to advance specific focus areas, identified through soliciting feedback from community leaders and healthcare providers, to help address HIV-related disparities in the South.

Emory University Rollins School of Public Health

For more than 25 years, public health leaders have pursued their quest for social justice and the elimination of health disparities at Emory University's Rollins School of Public Health. Rollins provides direct access to hands-on research and collaboration with the world's leading public health agencies. The school's scientists and educators have played a key role in HIV/AIDS from the earliest days of the epidemic. The Emory coordinating center will build on Emory's extensive history of HIV research, training and technical assistance to support organizational capacity-building. The Emory center will use a data-driven approach to identify geographic areas where organizational capacity-building will have the greatest impact.

University of Houston Graduate College of Social Work

The University of Houston Graduate College of Social Work (GCSW) is a nationally recognized program that prepares diverse leaders in practice and research to address complex challenges and achieve sustainable social, racial, economic and political justice, locally and globally, through exceptional education, innovative research and meaningful community engagement. GCSW research initiatives and community partnerships have fueled successful HIV programs for nearly a decade. The GCSW coordinating center will aim to enhance engagement and retention in care by incorporating attention to the role of wellness, trauma, mental health and substance use in HIV care, and increasing capacity to conduct comprehensive assessments using evidence-based screenings and appropriate follow-up care.



Southern AIDS Coalition

The mission of the Southern AIDS Coalition (SAC) is to end the HIV epidemic in the Southern United States. The SAC is a nonpartisan coalition of government, community and business leaders working alongside thousands of individual members to prevent new infections and build a South inclusive of people living with HIV. SAC does this through public health advocacy, capacity-building and education, research, and evaluation and strategic grant-making. The SAC coordinating center will develop and support education and advocacy efforts to address HIV-related stigma, discrimination and health inequities.

FOCUS

In communities that are heavily impacted by HIV, HCV and HBV, screening and diagnosis are the first steps to bringing care to the patients who need it. Gilead’s FOCUS program was created in 2010 with the goal to develop and share screening, diagnosis and linkage to care best practices with hospitals, community health centers and community-based organizations in these areas.

In 2017, FOCUS grew to encompass 169 partnerships in 83 cities and counties in the United States. The program’s geographic expansion has largely been driven by the recognized need for routine blood-borne virus screening and linkage to care in more rural areas of the country that are deeply impacted by the opioid and heroin epidemic. Since 2010, FOCUS partners have conducted 4.3 million HIV tests, 1.8 million HCV antibody tests and 106,000 HBV surface antigen tests.

To date, FOCUS partners have had more than 450 abstracts accepted to major conferences and have published 51 articles in peer-reviewed journals.

Community leaders from the Southern United States join Gilead in Atlanta for the launch of the Gilead COMPASS Initiative in December 2017.

FOCUS
by the numbers

6.2 Million
Blood-Borne Virus Tests Since 2010

4.3 Million
HIV tests

1.8 Million
HCV Ab Tests

106,000
HBV HBsAg Tests

83
Current Cities and Counties

STRATEGIC PARTNERSHIPS

Inadequate health infrastructures, financial challenges and societal barriers often keep patients in low- and middle-income countries from accessing the medicines they need. Through support programs and partnerships with leading health organizations, Gilead is improving global health by breaking down these barriers and helping to strengthen public health systems.

Partnering with WHO on Visceral Leishmaniasis

Since 1992, Gilead has supported the World Health Organization's (WHO) efforts to eliminate visceral leishmaniasis (VL), also known as kala-azar, a deadly parasitic disease plaguing poor and underserved communities in Southeast Asia.

As a result of Gilead's support, a total of 241 health facilities are equipped to diagnose VL, provide cold chain storage, and administer AmBisome® (amphotericin B liposome for injection) in Ethiopia, Sudan, South Sudan, Bangladesh, India and Nepal. This network of health facilities covers approximately 268 million at-risk individuals in regions where approximately 400,000 new cases of VL are identified each year. Without treatment, VL is nearly always fatal. Since 2013, 300,000 vials of AmBisome® have been distributed to the six affected countries above, free of charge.

Elton John AIDS Foundation Partnership

Gilead expanded its partnership with the Elton John AIDS Foundation (EJAF) in 2017 to include funding and medicines to support HIV and HCV initiatives. EJAF is a dynamic nonprofit organization whose mission is to end the AIDS epidemic by ensuring everyone

has the information and means to prevent infection and all people living with HIV have access to high-quality medical care and treatment. Through its partnership in the United States, Gilead and EJAF plan to reach an estimated 5,000 individuals living with HIV and another 10,000 at risk of HIV.

In 2017, EJAF, through the partnership with Gilead, announced the Key Populations Fund for Eastern Europe and Central Asia, focused on prevention and treatment of HIV and HCV among most vulnerable populations in the region. Over the course of three years, the fund will reach an estimated 20,000 people with HIV prevention, testing and related services. Gilead will also provide HCV medicines free of charge to approximately 5,000 patients in the region, where up to 97 percent of people living with HIV are co-infected with HCV.

Partnering with Emory to Develop Tools for Mapping Diseases and Epidemics

A key part of combating epidemic and endemic disease is the ability to visualize where diseases are occurring and how they are spreading. Through partnerships with universities and other organizations, Gilead is supporting the development of innovative tools to help visualize the state of HIV and HCV infection, which vary widely by community across the United States.



300,000 vials
of AmBisome distributed
in six countries

AIDSVu

Since 2010, Gilead has partnered with Emory University's Rollins School of Public Health to make HIV surveillance data widely available, easily accessible and locally relevant. The AIDSVu online interactive mapping tool enables users to visualize the U.S. HIV epidemic at the state, county and ZIP code levels. AIDSVu also features searchable service locators for HIV testing, prevention and care services.

HepVu

Building on the success of AIDSVu, Gilead and Emory launched HepVu in 2017 to visualize the first standardized state-level estimates of people living with past or current HCV infection. The estimates were generated by a disease-modeling project funded by the CDC. HepVu also maps rates of reported HCV mortality at the state level.

Young women in Uganda, a DREAMS intervention district. Photo credit: Helen Mansun/USAID

2017 PEPFAR Global Results

25%-40%

decline in new HIV diagnoses among adolescent girls and young women through DREAMS

15.2 million

voluntary medical male circumcisions to prevent infections in men and boys

2.2 million

babies born HIV-free, who would have otherwise likely been infected

85.5 million

people, including more than 11.2 million pregnant women, who received HIV testing

13.3 million

men, women and children who were on antiviral treatment

6.4 million

orphans and vulnerable children who received care and support

250,000

new healthcare workers trained to deliver HIV and other health services

Results based on PEPFAR data through September 30, 2017.



“Thank you to Gilead for your partnership in DREAMS. Because of your generous contribution, we’ve been able to provide pre-exposure prophylaxis for 25,000 girls. This supported our overall DREAMS results: In the 10 African countries (63 districts) implementing DREAMS, the majority (65 percent or 41 districts) of the highest HIV-burden districts achieved a decline in new diagnoses among adolescent girls and young women ages 15-24 by more than 25 percent since 2015, including 14 districts that had a decline of greater than 40 percent. Importantly, new diagnoses declined in nearly all DREAMS intervention districts.”

Ambassador Deborah L. Birx, M.D.

U.S. Global AIDS Coordinator & U.S. Special Representative for Global Health Diplomacy

DREAMS PEPFAR Partnership

Through a partnership with the United States President’s Emergency Plan for AIDS Relief (PEPFAR), Gilead and other partnering organizations aim to reduce HIV infections among adolescent girls and young women in 10 sub-Saharan African countries. The goal of DREAMS is to help girls develop into Determined, Resilient, Empowered, AIDS-free, Mentored and Safe women.

For the first time, the latest PEPFAR data show significant declines in new HIV diagnoses among adolescent girls and young women. In the 10 African countries (63 districts) implementing DREAMS, the majority (65 percent) of the highest HIV-burden communities or districts achieved up to 40 percent decline in new HIV diagnoses among young women. Importantly, new diagnoses declined in nearly all DREAMS intervention districts.



2016 Ebola Outbreak in Liberia

Responding to Ebola and Other Emerging and Neglected Viruses

Gilead's research and partnership efforts in emerging viruses such as Ebola reflect our determination to contain and eliminate threats to public health in all parts of the world. Gilead partners with organizations including United States and global public health agencies, non-governmental organizations, universities and defense agencies to develop responses to health threats such as Ebola, MERS, dengue and other infectious diseases in low- and middle-income countries.

By engaging partners with complementary expertise and resources — such as the trusted relationships that MSF have forged in vulnerable communities, or the high containment labs at Department of Defense that support research into the most dangerous pathogens — we are working to make innovative medicines available in places where they are most needed, quickly and effectively, in ways that reduce the risk in communities vulnerable to these pathogens.

In 2017, we collaborated with these partners to conduct nonclinical and clinical research advancing the development of investigational agent remdesivir (GS-5734):

National Institute of Allergy and Infectious Diseases (NIAID)

We continued an existing collaboration with NIAID in Liberia on testing remdesivir in Ebola survivors. The study expanded to Guinea in early 2018.

United States Army Medical Research Institute of Infectious Diseases

In collaboration with the United States Department of Defense, we have demonstrated the efficacy of remdesivir in the lethal nonhuman primate model of Marburg infection with similar efficacy as against Ebola. We filed an Investigational New Drug application with the FDA to conduct clinical trials for Marburg virus infection in February 2018.

United States Centers for Disease Control

In collaboration with the CDC, we have published a full broad-spectrum antiviral profile using in vitro data of remdesivir that includes not only Ebola, but also other pathogenic filoviruses (namely Marburg), coronaviruses (MERS, SARS) and paramyxoviruses (measles, Nipah, Hendra).

Doctors Without Borders/ Medecins Sans Frontieres (MSF)

Gilead has worked closely with MSF to build a plan for future outbreak responses to enable emergency use of remdesivir for individual patients in the event of Ebola or Marburg outbreaks.

University of North Carolina and Vanderbilt University

In collaboration with UNC and Vanderbilt, we characterized the in vivo efficacy of remdesivir against pathogenic coronaviruses (MERS and SARS). Results were published in the journal *Science Translational Medicine* in mid-2017. We are now engaging with key opinion leaders with a goal of initiating clinical testing in MERS-infected patients.

WHO

In September 2017, we were invited to present at WHO headquarters in Geneva, Switzerland, on the preclinical profile of remdesivir against MERS and SARS.

SUPPORTING ORGANIZATIONS THROUGH CORPORATE GIVING

In 2017, Gilead’s corporate giving program provided approximately \$400 million in cash donations to reduce health disparities, provide access to healthcare, advance education and support local communities around the world.

Reducing Disparities

People should have access to the same healthcare, regardless of their background. At Gilead, we fund projects that support underserved communities that have systematically experienced greater social or economic obstacles to health.

Black Women’s Health Imperative

Educating Black Women about HIV Prevention

Linda Goler Blount, President and CEO of Black Women’s Health Imperative (BWHI), knows that the collective power of Black women will move the needle on our health and wellness. Black women constitute about 13 percent of the female population in the United States but represent more than 60 percent of new HIV infections in women. BWHI is creating a platform for the voices that help give a very public and real face and story to the statistics in our communities.

These staggering statistics partly stem from the lack of education around HIV prevention in the Black community. “I had not heard of pre-exposure prophylaxis (PrEP),” says Washington, D.C., resident Gwendolyn Bell. “In two recent visits to the doctor, it has not been brought up to me.”

As part of BWHI’s comprehensive HIV prevention strategy, it recently launched a campaign to increase awareness of prevention tools such as PrEP. “Let’s Talk About PrEP” aims to educate women about HIV and the tools available to help protect against the disease. It uses social media and “guerrilla marketing” tactics to distribute educational materials, featuring positive imagery of strong Black women, in beauty



Linda Goler Blount, President and
CEO of Black Women’s Health Imperative

Black women represent:



13%

of the female population
in the United States



60%

of the new HIV infections in
women in the United States

salons and nightclubs around Atlanta, Baltimore and Washington, D.C.

BWHI is the only national organization dedicated exclusively to the health and wellness of the 21 million Black women and girls in the United States. “Our message is that you are in control. You can prevent HIV. You can protect yourself,” says Blount. “We can change the conversation from what’s wrong to what’s right.”

\$28 million

in grants to more than 120 organizations working to raise awareness about HIV prevention since 2012.

\$6 million

78 grants totaling almost \$6 million in 2017.



In 2017, **35%** of our total corporate grants were focused on improving access to healthcare worldwide.

HIV Prevention Grants

Biomedical interventions are important strategies for reducing new HIV infections, but behavioral and structural challenges continue to impact populations vulnerable to HIV. Gilead provides financial grants to independent community organizations that help raise awareness about PrEP among at-risk populations as part of a comprehensive HIV prevention strategy. We have provided more than \$28 million in grants to more than 120 organizations working to raise awareness about HIV prevention since 2012, including 78 grants, totaling almost \$6 million in 2017.

Providing Access

Through partnerships with other organizations, Gilead is working to overcome the barriers that prevent patients from accessing healthcare around the world. Gilead supports organizations that expand the capacity of healthcare systems, innovative models that help rural patients more easily access healthcare services, healthcare workforce training and other programs such as infrastructure/building health clinics that support underserved regions.

BLQ Checkpoint in Bologna

HIV and HCV Testing and Support for the Italian LGBT Community

Italy's first and only community HIV and HCV testing center, BLQ Checkpoint in Bologna, Italy, provides a comfortable and open environment for patients seeking diagnostic care.

Since opening in September 2015, BLQ Checkpoint, supported in part by Gilead, has conducted more than 2,500 tests for HIV and HCV at its center located in Bologna's city center. Through testing, BLQ Checkpoint also educates its clientele, primarily made up of the LGBT community, about HIV and HCV. Volunteers say that sharing information about HCV is especially important, as the disease is virtually unknown in Italy.

Each person at BLQ Checkpoint meets with a counselor to review the testing process and answer any questions. "I was getting tested at the hospital and now I do it here," says one 30-year-old client who visits regularly. BLQ Checkpoint also offers monthly meetings for gay men living with HIV, with topics such as the legal implications of being HIV positive, how to navigate family tensions and the continued need for HIV activism.

"The purpose of BLQ Checkpoint is simple: the patients come to take tests and some even come just to talk, to get rid of any doubts," says Gianfranco Spreafico, a BLQ Checkpoint volunteer.

Sandro Mattioli, President of Plus Onlus, the founding organization behind BLQ Checkpoint



Cancer Support Community

Patient Insights and Policy Improve Oncology Care

Linda House, president of Cancer Support Community (CSC), recognizes the importance of evidence-based practices in cancer care. As head of a leading organization helping to improve the experience of being a cancer patient, she draws upon her years of experience as an oncology nurse to develop programming, services and policies that have real impact.

CSC promotes patient-empowered care, an active approach to treatment aimed at making patients “the quarterback in their own health decisions, rather than passive recipients of treatment,” says House. In 2016, the organization’s Cancer Support Helpline fielded nearly 18,000 calls from patients, families and health professionals seeking information, access to resources and supportive counseling. Many patients called to ask for help navigating policy roadblocks, including affordability challenges, narrow insurance networks and long delays for treatment authorization — which limit their ability to achieve the best health outcomes.

To help mitigate those underlying policy issues, the CSC’s Cancer Policy Institute, sponsored in part by Gilead, brings together patient care insights from the organization’s 170 support service locations, which operate in four countries, which includes 22 U.S. states and Washington, D.C. These insights inform policymakers of the impact healthcare legislation has on patients.

For example, the Cancer Policy Institute recently launched a patient survey to better understand the full patient experience and some less-known costs of care. The survey mapped where patients incur additional costs in their treatment, such as time off work, transportation and special food or clothes, in order to identify potential cost savings.

“The goal of the Cancer Policy Institute is to use our research and patient insights to inform policymakers at the local, state and federal levels,” says House. “The future of cancer care needs to think about cancer as a comprehensive illness, not just a tumor.”



170

CSC support service locations for people impacted by cancer.



4

Operating in four countries, which includes 22 U.S. states and Washington, D.C.



18,000

In 2016, CSC’s Cancer Support Helpline fielded nearly 18,000 calls from patients, families and health professionals seeking information, access to resources and supportive counseling.



Patients and caregivers at an Immunotherapy Patients Summit sponsored by the Cancer Support Community, a global nonprofit whose services touch 1 million people.

Photo credit: Archival imagery supplied by Cancer Support Community.

Advancing Medical Education

Gilead strives to advance medical education worldwide. Effective education improves disease prevention and long-term disease management. We help community organizations by supporting disease awareness programs for patients and expanding knowledge and skills for healthcare professionals.

80%-90%

of Filipinos living with HBV contract it at birth, through mother-to-child transmission.

8 million

Filipinos affected by HBV.



of adult Filipinos are living with HBV.

Vhal Lucas



Hepatology Society of the Philippines

Raising Awareness of the HBV Epidemic in the Philippines

In 2008, Vhal Lucas and his immediate family tested positive for HBV. In the years that followed, he lost his three brothers to liver failure and liver cancer. This inexplicable tragedy inspired Vhal to support advocacy efforts led by the Hepatology Society of the Philippines, encouraging others to understand the consequences of not treating HBV.

The Hepatology Society of the Philippines is campaigning to increase awareness of HBV in the country. Its goal is to ensure that every Filipino is tested, vaccinated and treated for the disease, and to reduce stigma and discrimination against those who are living with HBV.

“In the Philippines, HBV is the leading cause of liver cancer. Sixteen percent of adult Filipinos are living with the disease. Eighty to 90 percent living with HBV contract it at birth, through mother-to-child transmission,” says Ian Homer Y. Cua, immediate past president of the Society. HBV affects almost 8 million Filipinos, many of whom ignore the diagnosis or try to manage it through diet.

“Lack of awareness leads to individuals not getting tested, not seeking care,” says Janus Ong, head of the Society. With support from Gilead, the Society launched a disease awareness campaign called “B Aware” to educate the public about hepatitis B risk factors, health consequences, treatment and prevention. The campaign reached Filipinos via advertisements on television, radio, billboards and buses, using celebrity endorsement to garner attention for its mission: to encourage Filipinos to “B Tested, B Vaccinated, B Treated.” On Facebook, more than 90,000 patients and their families saw it as a resource, which empowered them to speak out, ask questions and seek support.

Supporting Local Communities

Gilead understands how important it is for people of all backgrounds to live in vibrant local communities. Gilead funds initiatives that promote the well-being and betterment of communities in which we live and work, as well as neighborhoods in need.



Nearly **70%** of those enrolled in the Individual Placement and Support program at Fred Finch Youth Center achieve employment.

Staff members pause on the steps of Fred Finch Youth Center's historic administration building.

Photo credit: Archival imagery supplied by Fred Finch Youth Center.



Fred Finch Youth Center

Building on the Strengths of Disadvantaged Youth

Throughout his 30-year career, Tom Alexander, president and CEO of the Oakland, California-based Fred Finch Youth Center, has seen a major shift in the support of at-risk youth. Central to that shift is the inclusion of “wraparound” services, which form the basis of a community-based model for at-risk youth, disabled children and their caregivers and guardians.

This evidence-based approach brings services directly into communities, schools and family homes. The goal is to enable young people to live healthy and productive lives, which helps ensure more lasting results than those typically garnered from isolated residential programs, which were previously considered the standard of care.

One such program Fred Finch Youth Center employs, with support from Gilead, follows the Individual Placement and Support model (IPS) established by Dartmouth College. The program provides support and structure to youth ages 18 to 24 who are transitioning out of the foster care system and helps them gain competitive employment. Beyond resume skills and interview training, this program helps participants successfully launch into adulthood by earning financial independence and building self-esteem. Nearly 70 percent of those enrolled in IPS at Fred Finch Youth Center achieve competitive employment.

Established as an orphanage in 1891, the Fred Finch Youth Center continues to embody its founding principle that regardless of background, socioeconomic status or personal challenges, no one should be neglected or forgotten. “Kids have strength, no matter the hand they’re dealt,” says Alexander. “We owe it to them to capitalize on those strengths, rather than focus on the deficit.”